Results 101 to 110 of about 235,699 (346)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

New Records of Thecacineta cothurnioides and Trematosoma rotunda (Ciliophora, Suctorea) as epibionts on nematodes from the Indian Ocean [PDF]

open access: yes, 2009
This article deals with the report of two suctorian ciliates species viz. Thecacineta cothurnioides Collin, 1909 and Trematosoma rotunda (Allgén, 1952 ) as epibionts on Tricoma sp. and Pseudochromadora sp.
Chatterjee, Taras   +2 more
core  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

The fauna of brackish ponds at Port Canning, lower Bengal : Part VII: further observations on the Polyzoa, with the description of a new genus of Entoprocta [PDF]

open access: yes, 2009
A considerable change has taken place in the Polyzoa of the ponds this winter, apparently owing to last summer's floods, which broke down the embankment that separated the ponds from the river, joining thelll together temporarily.
Annandale, Nelson
core  

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Short Season Corn Silage Performance Trial Summary [PDF]

open access: yes, 2017
Conducted by Dr. Heather Darby and the University of Vermont Northwest Crops and Soils Program Short season corn (80-97 day relative maturity) silage hybrids in Alburgh, VT Planting Date: 5/18/2017 Harvest Date: 9/20 ...
Darby, Heather
core   +8 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Young People, Stalking Awareness and Domestic Abuse [PDF]

open access: gold, 2023
Maria Mellins   +2 more
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Home - About - Disclaimer - Privacy